Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Scientists at University of Tubingen discuss research in angiogenesis
February 24th, 2009
"Advanced hepatocellular cancer (HCC) is a highly vascularised tumor with limited treament options. We wanted to evaluate the impact of different treatments on systemic biomarkers linked to angiogenesis," scientists writing in the Journal of Cancer Research and Clinical Oncology report. "Two subsequent prospective, randomised, phase-I/II trials in patients with advanced HCC were performed. A total of 38 patients was randomised to a total of 4 regimens consisting of 3 cycles of 4 weeks each: Trial 1 included group 1 receiving octreotide 30 mg im on day 1, and group 2 octreotide 30 mg on day 1 plus Imatinib 400 mg po daily; Trial 2 included group 3 with oxaliplatin...
Source: Cancer Weekly (2009-02-24)
|
